Immunotherapy in association with stereotactic radiotherapy for Non-Small Cell Lung Cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO
| Autor: | Giancarlo Beltramo, Emanuela Olmetto, Valentina Pinzi, Paolo Muto, Isacco Desideri, Umberto Ricardi, Mattia Falchetto Osti, Lorenzo Livi, Sara Pedretti, Guido Pecchioli, Alessio Bruni, P. Matteucci, Niccolò Giaj-Levra, Anna Merlotti, Ernesto Maranzano, Laura Fariselli, Paola Anselmo, Paolo Tini, Marco Krengli, Cristina Mantovani, Pierina Navarria, Francesco Pasqualetti, Saverio Caini, Rossella Di Franco, Silvia Scoccianti, Emilia Giudice, Patrizia Ciammella, Vieri Scotti, Davide Franceschini, Marianna Trignani |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Clinical Investigations Radiosurgery 03 medical and health sciences 0302 clinical medicine Internal medicine Carcinoma Non-Small-Cell Lung medicine Stereotactic radiotherapy Combined Modality Therapy Humans Progression-free survival Lung cancer Non-Small-Cell Lung Retrospective Studies brain metastases immunotherapy non-small cell lung cancer radiosurgery stereotactic radiotherapy Immunotherapy Brain Neoplasms Carcinoma business.industry Retrospective cohort study Brain metastases Non-Small Cell Lung Cancer medicine.disease Radiation therapy 030220 oncology & carcinogenesis Toxicity Adenocarcinoma Neurology (clinical) business human activities 030217 neurology & neurosurgery |
| Zdroj: | Neuro Oncol |
| Popis: | Background To define efficacy and toxicity of Immunotherapy (IT) with stereotactic radiotherapy (SRT) including radiosurgery (RS) or hypofractionated SRT (HFSRT) for brain metastases (BM) from non-small cell lung cancer (NSCLC) in a multicentric retrospective study from AIRO (Italian Association of Radiotherapy and Clinical Oncology). Methods NSCLC patients with BM receiving SRT + IT and treated in 19 Italian centers were analyzed and compared with a control group of patients treated with exclusive SRT. Results One hundred patients treated with SRT + IT and 50 patients treated with SRT-alone were included. Patients receiving SRT + IT had a longer intracranial Local Progression-Free Survival (iLPFS) (propensity score-adjusted P = .007). Among patients who, at the diagnosis of BM, received IT and had also extracranial progression (n = 24), IT administration after SRT was shown to be related to a better overall survival (OS) (P = .037). A multivariate analysis, non-adenocarcinoma histology, KPS = 70 and use of HFSRT were associated with a significantly worse survival (P = .019, P = .017 and P = .007 respectively). Time interval between SRT and IT ≤7 days (n = 90) was shown to be related to a longer OS if compared to SRT-IT interval >7 days (n = 10) (propensity score-adjusted P = .008). The combined treatment was well tolerated. No significant difference in terms of radionecrosis between SRT + IT patients and SRT-alone patients was observed. The time interval between SRT and IT had no impact on the toxicity rate. Conclusions Combined SRT + IT was a safe approach, associated with a better iLPFS if compared to exclusive SRT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|